BCWM
TPTX

Bartlett & Co Wealth Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bartlett & Co Wealth Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3
Closed -$234 – 1092
2021
Q2 		$234 Hold
3
– – ﹤0.01% 1055
2021
Q1 		$284 Hold
3
– – ﹤0.01% 1082
2020
Q4 		$366 Buy
+3
New +$329 ﹤0.01% 1173

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bartlett & Co Wealth Management's TPTX Position: Q3 2021 in Review

Bartlett & Co Wealth Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2021, closing a stake of 3 shares — an estimated $234 sold.

Bartlett & Co Wealth Management first reported a position in TPTX in Q4 2020 and held it in 3 quarters. The position peaked at $366 in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q3 2021.

  • Bartlett & Co Wealth Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 3 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $234.
  • Bartlett & Co Wealth Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Bartlett & Co Wealth Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $366 in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Bartlett & Co Wealth Management's 13F filing for Q3 2021, filed 14 Feb 2024.